Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2013 2
2014 4
2015 2
2016 3
2017 5
2018 4
2019 6
2020 5
2021 3
2022 4
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Results by year

Filters applied: . Clear all
Page 1
The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis.
Loscocco GG, Rotunno G, Mannelli F, Coltro G, Gesullo F, Pancani F, Signori L, Maccari C, Esposito M, Paoli C, Vannucchi AM, Guglielmelli P. Loscocco GG, et al. Among authors: paoli c. Am J Hematol. 2024 Jan;99(1):68-78. doi: 10.1002/ajh.27136. Epub 2023 Oct 17. Am J Hematol. 2024. PMID: 37846894
Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score.
Barbui T, Ghirardi A, Carobbio A, Masciulli A, Carioli G, Rambaldi A, Finazzi MC, Bellini M, Rumi E, Vanni D, Borsani O, Passamonti F, Mora B, Brociner M, Guglielmelli P, Paoli C, Alvarez-Larran A, Triguero A, Garrote M, Pettersson H, Andréasson B, Barosi G, Vannucchi AM. Barbui T, et al. Among authors: paoli c. Blood Cancer J. 2022 Nov 16;12(11):156. doi: 10.1038/s41408-022-00743-0. Blood Cancer J. 2022. PMID: 36385103 Free PMC article. No abstract available.
Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis.
Mannelli F, Bencini S, Coltro G, Loscocco GG, Peruzzi B, Rotunno G, Maccari C, Gesullo F, Borella M, Paoli C, Caporale R, Mannarelli C, Annunziato F, Guglielmelli P, Vannucchi AM. Mannelli F, et al. Among authors: paoli c. Am J Hematol. 2022 Jul;97(7):846-855. doi: 10.1002/ajh.26548. Epub 2022 Mar 31. Am J Hematol. 2022. PMID: 35338671 Free PMC article.
ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera.
Guglielmelli P, Coltro G, Mannelli F, Rotunno G, Loscocco GG, Mannarelli C, Maccari C, Paoli C, Romagnoli S, Bartalucci N, Vannucchi AM. Guglielmelli P, et al. Among authors: paoli c. Blood Adv. 2022 May 10;6(9):2927-2931. doi: 10.1182/bloodadvances.2021006350. Blood Adv. 2022. PMID: 35020812 Free PMC article. No abstract available.
JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis.
Guglielmelli P, Loscocco GG, Mannarelli C, Rossi E, Mannelli F, Ramundo F, Coltro G, Betti S, Maccari C, Ceglie S, Chiusolo P, Paoli C, Barbui T, Tefferi A, De Stefano V, Vannucchi AM. Guglielmelli P, et al. Among authors: paoli c. Blood Cancer J. 2021 Dec 11;11(12):199. doi: 10.1038/s41408-021-00581-6. Blood Cancer J. 2021. PMID: 34897288 Free PMC article.
Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study.
Guglielmelli P, Ghirardi A, Carobbio A, Masciulli A, Maccari C, Mora B, Rumi E, Triguero A, Finazzi MC, Pettersson H, Paoli C, Mannelli F, Vanni D, Rambaldi A, Passamonti F, Alvarez-Larràn A, Andreasson B, Vannucchi AM, Barbui T. Guglielmelli P, et al. Among authors: paoli c. Blood Adv. 2022 Jan 25;6(2):373-375. doi: 10.1182/bloodadvances.2021006006. Blood Adv. 2022. PMID: 34753179 Free PMC article. No abstract available.
Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients.
Loscocco GG, Guglielmelli P, Gangat N, Rossi E, Mannarelli C, Betti S, Maccari C, Ramundo F, Jadoon Y, Gesullo F, Ceglie S, Paoli C, Pardanani A, De Stefano V, Tefferi A, Vannucchi AM. Loscocco GG, et al. Among authors: paoli c. Am J Hematol. 2021 Nov 1;96(11):1472-1480. doi: 10.1002/ajh.26332. Epub 2021 Sep 6. Am J Hematol. 2021. PMID: 34424575 Free PMC article.
Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study.
Vannucchi AM, Sordi B, Morettini A, Nozzoli C, Poggesi L, Pieralli F, Bartoloni A, Atanasio A, Miselli F, Paoli C, Loscocco GG, Fanelli A, Para O, Berni A, Tassinari I, Zammarchi L, Maggi L, Mazzoni A, Scotti V, Falchetti G, Malandrino D, Luise F, Millotti G, Bencini S, Capone M, Piccinni MP, Annunziato F, Guglielmelli P; RUXO-COVID Study Group. Vannucchi AM, et al. Among authors: paoli c. Leukemia. 2021 Apr;35(4):1121-1133. doi: 10.1038/s41375-020-01018-y. Epub 2020 Aug 19. Leukemia. 2021. PMID: 32814839 Free PMC article. Clinical Trial.
A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia.
Rocca B, Tosetto A, Betti S, Soldati D, Petrucci G, Rossi E, Timillero A, Cavalca V, Porro B, Iurlo A, Cattaneo D, Bucelli C, Dragani A, Di Ianni M, Ranalli P, Palandri F, Vianelli N, Beggiato E, Lanzarone G, Ruggeri M, Carli G, Elli EM, Carpenedo M, Randi ML, Bertozzi I, Paoli C, Specchia G, Ricco A, Vannucchi AM, Rodeghiero F, Patrono C, De Stefano V. Rocca B, et al. Among authors: paoli c. Blood. 2020 Jul 9;136(2):171-182. doi: 10.1182/blood.2019004596. Blood. 2020. PMID: 32266380 Free article. Clinical Trial.
36 results